Soft tissue tumors : clear cell sarcoma by Poppe, Bruce et al.
   
 
 
 
 
 
Solid Tumour Section 
Mini Review 
 
Atlas Genet Cytogenet Oncol Haematol. 2003; 7(1)  
 
49 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
Soft tissue tumors: Clear cell sarcoma 
Bruce Poppe, Ramses Forsyth, Karl Dhaene, Frank Speleman 
Centre for Medical Genetics, 1K5, University Hospital Ghent, De Pintelaan 185, 9000 Gent, Belgium (BP, 
FS) 
 
Published in Atlas Database: November 2002 
Online updated version : http://AtlasGeneticsOncology.org/Tumors/ClearCellSarcID5074.html 
DOI: 10.4267/2042/37939 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2003 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Identity 
Alias 
Clear cell sarcoma of the tendons and aponeuroses 
Malignant melanoma of the soft parts 
 
Nests of clear polygonal cells delineated by fibrous septa (HE, 200x). 
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Clinics and pathology 
 
Cellular smear almost exclusively showing dispersed spindle cells. Their oval nuclei are only slightly irregular and contain a large 
nucleolus. The cytoplasm is rather scant (MGG, 400x) (Courtesy of Dr. J. Willems, Onze-Lieve-Vrouw Ziekenhuis Aalst, Belgium). 
 
Disease 
Soft tissue tumour, presenting as a slow growing mass 
intimately associated with tendons and aponeuroses, in 
young adults. 
Note 
To be distinguished from clear cell sarcoma of the 
kidney, to which it is unrelated. 
Embryonic origin 
Mesoderm. 
Epidemiology 
Rare sarcoma affecting primarily young adults 
Clinics 
Slowly growing tumour mass, causing pain or 
tenderness, particularly frequently (up to 95% of the 
cases) situated in the extremities, with a predilection 
for the foot and the ankle. 
Pathology 
Polygonal or spindle shaped cells with abundant 
eosinophilic or clear cytoplasm displaying a uniform, 
nested to fascicular growth pattern, delineated by 
fibrous septa. Melanin deposits can be demonstrated 
using specific stains, but is more readily detectable by 
immunoreactivity against melanoma antigens (e.g. 
S100 and HMB45) in the vast majority of the cases. 
Treatment 
Radical surgical resection, adjuvant radiotherapy 
should be considered in incomplete resections, large 
(>5 cm) tumours and/or high grade lesions. Clear cell 
sarcomas seem to display little sensitivity to 
conventional soft tissue sarcoma multi-agent 
chemotherapy protocols. 
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Left to right: A: Typical clear cell sarcoma with eosinophilic cytoplasm (H&E, 400x); B: A reticulin meshwork surrounds the individual 
nests (reticulin, 200x); C: Strong S100 immunoreactivity, a consistent feature (S100, 400x). 
 
Evolution 
Special attention should be paid to the occurrence of 
late recurrences (median time to recurrence: 4.2 years). 
Prognosis 
Generally, clear cell sarcoma is characterised by an 
adverse prognosis, only 40 to 50% of the patients being 
long-term survivors. As recurrences may occur late, 5-
year survival rates tend to misjudge prognosis. 
Established prognostic features include: tumour size, 
necrosis and local recurrence. 
Cytogenetics 
 
The t(12;22)(q13;q12), as identified by G-banding. 
Cytogenetics Morphological 
The cytogenetic hallmark of clear cell sarcoma is the 
presence of the t(12;22)(q13;q12). This translocation 
has been described in the majority of reported clear cell 
sarcoma cases, not however in other malignancies. The 
translocation is readily identifiable with G-, R- or Q-
banding. 
Cytogenetics Molecular 
Fluorescence in situ hybridisation based approaches 
can be used to demonstrate the t(12;22), using 
chromosome painting probes or to demonstrate EWSR1 
and ATF1 gene rearrangement, using gene specific 
probes. 
 
Dual colour in situ hybridisation the EWS cosmid G9 (green) 
and the ATF1 CCS2.2 cosmid (red) demonstrating a 
juxtaposition of 5' EWS to 3' ATF1 sequences, indicating the 
presence of a EWS/ATF1 genomic fusion (arrowheads). 
Probes 
EWSR1 probes: 5' EWSR1: G9 cosmid; 3' ATF1 
probe: CCS2.2 
Additional anomalies 
Although the t(12;22) has been reported as the sole 
chromosomal aberration in clear cell sarcoma, most 
cases display additional cytogenetic anomalies, 
including +7, +8 and structural and numerical 
aberrations of chromosome 22. 
Variants 
No variant translocations, creating EWSR1/ATF1 
fusion transcripts, have been described. 
Genes involved and proteins 
EWSR1 
Location 
22q13 
Note 
Also called EWS. 
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DNA / RNA 
EWSR1 is transcribed from centromere to telomere at 
22q12. The coding sequence contains 1971 bp, 
comprising 17 exons and spans approximately 32 kb. 
Alternative splicing creates the EWS-b variant, lacking 
exons 8 and 9. 
Protein 
The EWS protein contains a C-terminal RNA binding 
domain and has indeed been shown to display RNA 
binding properties. The functions of the EWS protein, 
however, largely remain elusive. 
ATF1 
Location 
12q13 
DNA / RNA 
ATF1 is transcribed from centromere to telomere at 
12q13. The coding sequence contains 816 bp, 
comprising 6 exons and spans approximately 43 kb. 
Protein 
ATF1 encodes a member of the CREB/ATF basic 
leucine-zipper type transcription factor family and 
binds to cAMP inducible promotors. 
Result of the chromosomal 
anomaly 
Hybrid Gene 
Description 
The EWS/ATF1 fusion transcript is detectable in up to 
90% of the clear cell sarcoma cases. As described in 
other EWS rearrangements, the transcript fuses 5' EWS 
to 3' heterologous sequences. The reciprocal 
ATF1/EWS fusion probably does not contribute to 
malignant transformation since it is out of frame. 
Transcript 
Several alternatively spliced transcripts have been 
described, the more frequent being the type 1 fusion: 
EWS exon 8 fused to ATF1 exon 4. 
Fusion Protein 
Oncogenesis 
The EWS/ATF1 oncoprotein converts ATF1 to a 
constitutive transcriptional activator that represses 
p53/CBP-mediated transactivation. 
 
 
Detection protocole: as described by Antonescu et al. (the data given are virtually identical to the Table 1 from the mentioned reference). 
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